866-997-4948(US-Canada Toll Free)

Mitomycin (Bladder Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Bladder Cancer

No. of Pages : 32 Pages

 

GlobalDatas pharmaceuticals report, Mitomycin (Bladder Cancer) Analysis and Forecasts to 2020 provides Javlor global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Bladder Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Mitomycin including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Mitomycin including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Global sales forecast for 2002-2020 for Mitomycin

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

 

Table of content

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3

2 Introduction 4
2.1 Bladder Cancer Market 4
2.2 Bladder Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 8

3 Baldder Cancer Disease: Market Characterization 9
3.1 Bladder Cancer Disease Market 9
3.2 Bladder Cancer Disease Market Forecasts and CAGR 9
3.3 Drivers for the Bladder Cancer Disease Market 9
3.3.1 High Prevalence 10
3.3.2 High Incidence 10
3.3.3 High Survival Rate 11
3.3.4 High lifetime costs 11

4 TNM Classification of bladder cancer 12
4.1 American Urological Association 12

5 Mitomycin (Mutamycin) 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Mitomycin Monograph 15
5.4 Treatment Regimen 15
5.4.1 Low Risk Patients 15
5.4.2 Intermediate Risk Patients 16
5.4.3 High Risk Patients 16
5.4.4 BCG Intolerant Patients 16
5.4.5 Device Assisted Chemotheraphy Instillations 16
5.5 Clinical Studies 17
5.5.1 Controlled Studies 17
5.5.2 Finnbladder IV Study 18
5.5.3 Clinical Study: Chemotherapy after TUR 19
5.5.4 Efficacy comparison of various agents for BCG failures 20
5.6 Maintenance with Mitomycin 21
5.7 Sequential Chemoimmunotherapy 21
5.7.1 Clinical Trial 22
5.7.2 Results 22
5.7.3 Conclusion 24
5.8 Sales drivers 24
5.8.1 Bladder Cancer Market 24
5.8.2 Better Efficacy than other Chemotherapy agents 24
5.8.3 Reduced rate of Recurrence 25
5.9 Drug Evaluation 25
5.9.1 Drug Risk Benefit Score 25
5.9.2 Intensity of Competition 27
5.10 Sales forecast 28
5.10.1 Target patient Pool of Mitomycin 28
5.10.2 Dosing 29
5.10.3 Market Penetration 29
5.10.4 Annual Cost of Therapy 29
5.10.5 Sales Projections of Mitomycin 29

6 Bladder Cancer Market: Appendix 30
6.1 Market Definitions 30
6.2 List of Abberiviations30
6.3 Research Methodology 30
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 31
6.3.4 Number of Patients Approved to take the Drug 31
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 31
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 32
6.5 Disclaimer 32
6.6 Sources 32

 

List of Table


Table 1: Bladder Cancer Incidences & Mortality 5
Table 2: Bladder Cancer, Global, Market Forecast ($bn), 20022020 9
Table 3: Clinical Trials: Net effect on Recurrence and Progression 19
Table 4: Tumor Recurrence: Intravesical Mitomycin vs. Control 21
Table 5: Means and Standard Deviations (SD) for Recurrence Rate and Recurrence Index Before and After treatment 23
Table 6: Drug Risk Benefit Score of Mitomycin (low risk patients) 26

List of Chart


Figure 1: Percentage Distribution of Top 20 Diagnosed Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 6
Figure 3: Percentage share of risk factors in Developed Countries 6
Figure 4: Percentage share of risk factors in Developing Countries 7
Figure 5: Smoking Consumption Curve, US 7
Figure 6: Forecasted Global Bladder Cancer Market($bn), 2009-2020 9
Figure 7: All Cancer Incidence Worldwide 10
Figure 8: Bladder Cancer Incidence Worldwide 10
Figure 9: Broad Classification of Bladder Cancer 12
Figure 10: Classification of NMI Bladder Cancer 12
Figure 11: Detailed TNM Classifications 13
Figure 12: TNM staging of urothelial tract cancers: Stage I to Stage IV 14
Figure 13: Classification of NMI Bladder Cancer 14
Figure 14: Comparison of Complete Response Rate: Mitomycin and Mitomycin+ EMDA 17
Figure 15: Effect of Intravesical Chemotherapy on Recurrence Rates 18
Figure 16: Finnbladder IV Clinical study 18
Figure 17: Net Benefit on Recurrence rate (%) of chemotherapy after TUR 19
Figure 18: : Net Benefit on Progression rate (%) of chemotherapy after TUR 20
Figure 19: Efficacy comparison of various agents for BCG failures 20
Figure 20: Tumor Recurrence: Intravesical Mitomycin vs. Control group 21
Figure 21: Time schedule for therapy instillations 22
Figure 22: Number of Recurrent Tumors for patients with BCG and BCG+ MMC 23
Figure 23: Efficacy Comparison of Mitomycin with other theuraptic agents 25
Figure 24: Complete Response for Different Therapies : Papillary Tumor 26
Figure 25: Complete response for CIS Tumor 27
Figure 26: Drug Model Diagram of Mitomycin 28
Figure 27: Global Forecasted Sales of Mitomycin & Sales Distribution 29
Figure 28: Distribution of Mitomycin sales in Major Countries 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *